| Dr Eric B Atwood, DO | |
|
1200 Schwegler Dr Rm 2100, Lawrence, KS 66045-1963 | |
| (785) 864-2277 | |
| (785) 864-2721 |
| Full Name | Dr Eric B Atwood |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1200 Schwegler Dr Rm 2100, Lawrence, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902917727 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 521953 (Kansas) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 05-21953 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric B Atwood, DO 1200 Schwegler Dr Rm 2100, Lawrence, KS 66045-7538 Ph: (785) 864-2277 | Dr Eric B Atwood, DO 1200 Schwegler Dr Rm 2100, Lawrence, KS 66045-1963 Ph: (785) 864-2277 |
News Archive
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
A model developed using artificial intelligence is better at predicting risk of death in patients with heart disease than models designed by medical experts, a new study from the Francis Crick Institute shows.
High levels of public support for strict measures to control COVID-19 during the first wave of the pandemic did not reflect high levels of public trust in the UK government's honesty, transparency or motives, suggests a new study published in PLOS One.
A team of researchers from the University of Minnesota and The Dow Chemical Company have discovered a new method for customizing ingredients that help oral medications dissolve in the body and be absorbed into the bloodstream.
› Verified 5 days ago
Timothy Jason Mccord, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Maine St Ste A, Lawrence, KS 66044 Phone: 785-843-9192 Fax: 785-856-9191 | |
Dr. Sanjeev Kumar, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1130 W 4th St Ste 3203, Lawrence, KS 66044 Phone: 785-832-1424 Fax: 785-505-5260 | |
Dr. Linda Lorene Keeler, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1200 Schwegler Dr, Watkins Health Center 2100, Lawrence, KS 66045 Phone: 785-864-2277 Fax: 785-864-2721 | |
Joe Douglas, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 200 Maine, Suite A, Lawrence, KS 66044 Phone: 785-843-9192 Fax: 785-856-9191 | |
Dr. John D Clark, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1130 W 4th St Ste 3203, Lawrence, KS 66044 Phone: 785-830-8324 Fax: 785-505-5260 | |
Dr. Paul D Morte, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1112 W 6th St, Ste 218, Lawrence, KS 66044 Phone: 785-842-8240 Fax: 785-842-7474 | |
Dr. C. Shaffia Laue, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1025 Kentucky St, Lawrence, KS 66044 Phone: 785-841-1243 Fax: 785-841-1243 |